BioAxone Biosciences Inc. is a biotechnology company with a focus on regenerative medicine for unmet medical needs. The company is specialized in the development and commercialization of proprietary medicines targeting Rho signaling, a key target pathway for treating neurotrauma and neurological disease. BioAxone is pursuing an aggressive and focused strategy to treat spinal cord injury around its lead compound, Cethrin™.
Cethrin™ (BA-210) is BioAxone’s lead clinical-stage drug with excellent prospects for rapid FDA approval for treatment of acute spinal cord injury. Cethrin is a biologic drug, and a therapeutic protein protected by an impressive estate of issued patents that protect Cethrin and derivatives of Cethrin. BioAxone also has a strong preclinical data for the use of BA-210 in other unmet needs that include traumatic brain injury, traumatic optic neuropathy, and optic nerve ischemia.
BioAxone also has a strong preclinical pipeline that include novel Rho kinase inhibitors, and a discovery program. The discovery program is in collaboration with Advirna, an RNA company, to create novel RNAi drugs to treat various neurological conditions